Skip to main content
SpringerLink
Log in

Dendritische Zellen und andere neue Vakzinationsstrategien zur Therapie des Melanoms und anderer Tumoren

  • Conference paper
Dermatologie an der Schwelle zum neuen Jahrtausend

  • 9 Accesses

Zusammenfassung

Es ist heute sicher, daß das Immunsystem über Abwehrzellen, insbesondere CD8 positive zytotoxische T-Zellen (CTL) verfügt, welche Tumorantigene erkennen und so Tumorzellen spezifisch abtöten können [18], [30]. Ein wesentliches Problem ist allerdings, daß diese T-Zellen entweder im Patienten überhaupt nicht induziert werden oder nur sehr schwach und transient. Eine wahrscheinliche Erklärung dafür ist, daß die dendritischen Zellen (DZ), das „Adjuvans der Natur“, Tumorantigene in vivo nur sehr schlecht präsentieren [26], ein weiterer Mechanismus könnte die Tolerisierung tumorreaktiver T-Zellen durch die Tumoren sein [18]. DZ sind für die Einleitung sämtlicher Immunantworten notwendig [2]. Unreife DZ nehmen Antigene in der Peripherie auf und prozessieren diese in MHC-Peptid-Komplexe (aufgenommene lösliche oder partikuläre Antigene in den sog. Klasse-II Pathway, phagozytierte apoptotische Zellen in den sog. Klasse-I Weg) [1],[2]. Die unreifen DZ verfügen allerdings noch nicht über die volle T-Zell-stimulatorische Aktivität.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTL2. Nature 392:86–89

    Article  PubMed  CAS  Google Scholar 

  2. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 393:245–252

    Article  Google Scholar 

  3. Becker JC, Brabletz T, Czerny C, Termeer C, Bröcker EB (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 5:1501–1508

    Article  PubMed  CAS  Google Scholar 

  4. Becker JC, Termeer C, Schmidt RE, Bröcker EB (1993) Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151:7224–7232

    PubMed  CAS  Google Scholar 

  5. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–447

    Article  PubMed  CAS  Google Scholar 

  6. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68

    Article  PubMed  CAS  Google Scholar 

  7. Enk AH, Jonuleit H, Saloga J, Knop J (1997) Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73:309–316

    Article  PubMed  CAS  Google Scholar 

  8. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE et al. (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Nature 274:1363–1366

    CAS  Google Scholar 

  9. Inaba K, Steinman RM, Witmer-Pack M, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G (1992) Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175:1157–1167

    Article  PubMed  CAS  Google Scholar 

  10. Jäger E, Ringhoffer M, Dienes HP, Arand, M, Karbach J et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54–62

    Article  PubMed  Google Scholar 

  11. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J et al. (1997) Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142–147

    Article  PubMed  Google Scholar 

  12. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM (1998) Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 188:1493–1501

    Article  PubMed  CAS  Google Scholar 

  13. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625–631

    Article  PubMed  CAS  Google Scholar 

  14. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH et al (1999, in press) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene Mage-3 and presented by HLA-Al. Int J Cancer, in press

    Google Scholar 

  15. McMichael Andrew J, O’Callaghan CA (1998) A new look at T cells. J Exp Med 187:1367–1371

    Article  Google Scholar 

  16. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B (1997) In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313–321

    Article  PubMed  CAS  Google Scholar 

  17. Nestle FO, Alijagic S, Gilliet M, Gilliet M, Sun Y, Grabbe S et al. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332

    Article  PubMed  CAS  Google Scholar 

  18. Pardoll DM (1998) Cancer vaccines. Nat Med (Vaccine Suppl) 4:525

    Article  CAS  Google Scholar 

  19. Pitti RM, Masters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703

    Article  PubMed  CAS  Google Scholar 

  20. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell precursors in human blood. J Exp Med 180:83–93

    Article  PubMed  CAS  Google Scholar 

  21. Romani N, Reider D, Heuer M, Ebner S, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunological Methods 196:137–151

    Article  CAS  Google Scholar 

  22. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650

    Article  PubMed  CAS  Google Scholar 

  23. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola F, Topalian S et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoms. Nat Med 4:321–327

    Article  PubMed  CAS  Google Scholar 

  24. Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539–542

    Article  PubMed  CAS  Google Scholar 

  25. Schreiber S, Kämpgen E, Wagner E, Pirkhammer, Trcka J, Korschan H et al. (1999) Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous IL-2-transfected Cancer Cells 73-Outcome of a Phase I Study. Human Gene Ther, in press

    Google Scholar 

  26. Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183–1187

    Article  PubMed  CAS  Google Scholar 

  27. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141–13146

    Article  PubMed  CAS  Google Scholar 

  28. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186:645–653

    Article  PubMed  CAS  Google Scholar 

  29. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Kämpgen E, Bender A, Schuler G (1998) Generation of large numbers of fully mature and stable dendritic cells form leukapheresis products for clinical application. J Immunol Methods 223:1–15

    Article  Google Scholar 

  30. Van den Eynde B, Van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693

    Article  PubMed  Google Scholar 

  31. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H (1997) Antigenic cancer cells grow progressively in immune hosts without evidence for T cells exhaustion or systemic anergy. J Exp Med 186:229–238

    Article  PubMed  CAS  Google Scholar 

  32. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4:594–600

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Thurner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Enk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Kämpgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Dermatologie, Allgemeines Krankenhaus St. Georg, Lohmühlenstraße 5, D-20099, Hamburg, Deutschland

    A. Plettenberg  & Wilhelm N. Meigel  & 

  2. Hautklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-20246, Hamburg, Deutschland

    Ingrid Moll

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Schuler, G., Thurner, B., Enk, A., Kämpgen, E. (2000). Dendritische Zellen und andere neue Vakzinationsstrategien zur Therapie des Melanoms und anderer Tumoren. In: Plettenberg, A., Meigel, W.N., Moll, I. (eds) Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57191-6_139

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57191-6_139

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63042-2

  • Online ISBN: 978-3-642-57191-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation